Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | HTRA2 | O43464 | 6/20 | 0.49 |
| ▸ | HTRA1 | Q92743 | 6/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | HTR3A | P46098 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17245794 | 1.00 | FOLH1 (0.55) | FOLH1CA12CA1CA2CA9 | |
| SCHEMBL20843781 | 0.95 | FOLH1 (0.56) | FOLH1CA12CA1CA2CA9 | |
| SCHEMBL17245299 | 0.95 | FOLH1 (0.56) | FOLH1CA12CA1CA2CA9 | |
| SCHEMBL21183304 | 0.93 | FOLH1 (0.53) | FOLH1CA12CA1CA2CA9 | |
| SCHEMBL21183297 | 0.93 | FOLH1 (0.54) | FOLH1CA12CA1CA2CA9 | |
| SCHEMBL15505788 | 0.92 | FOLH1 (0.54) | FOLH1CA12CA1CA2CA9 | |
| SCHEMBL21187074 | 0.90 | FOLH1 (0.53) | FOLH1CA12CA1CA2CA9 | |
| SCHEMBL20622392 | 0.90 | FOLH1 (0.54) | FOLH1CA12CA1CA2CA9 | |
| SCHEMBL22414021 | 0.90 | FOLH1 (0.54) | FOLH1CA12CA1CA2CA9 | |
| SCHEMBL15505808 | 0.90 | FOLH1 (0.64) | FOLH1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170290900-A1 | CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS | PURDUE RESEARCH FOUNDATION | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290900-A1 | CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS | CD4, CD2, CD47 | FOLH1 279/4885CA12 80/4885CA1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.